Združene države Amerike - angleščina - NLM (National Library of Medicine)

hospira, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - potassium chloride 1.79 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw need

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient. none known. to open: tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for administration (use aseptic technique) - close flow control clamp of administration set. - remove cover from outlet port at bottom of container. - insert piercing pin of administration set into port with a twisting motion until the set is firmly seated.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

amneal pharmaceuticals llc - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). oxybutynin chloride extended-release tablets are contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma. oxybutynin chloride extended-release tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. there have been reports of hypersensitivity reactions, including anaphylaxis and angioedema. risk summary there are no adequate data on oxybutynin chloride extended-release tablets use in pregnant women to

Združene države Amerike - angleščina - NLM (National Library of Medicine)

terumo bct ltd. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium gluconate (unii: r6q3791s76) (gluconic acid - unii:r4r8j0q44b, sodium cation - unii:lyr4m0nh37), sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - uni - sodium chloride 0.53 g in 100 ml - isoplate solution - platelet additive solution [pas-f] is an isotonic solution to replace a portion of the plasma to store platelets pheresis platelet additive solution (pas) added leukocytes reduced products collected using a hyperconcentrated collection on terumo bct's trima accel system [see dosage and administration (2).] platelets pheresis pas added leukocytes reduced products are stored in a mix of 65% isoplate solution and 35% plasma. platelets in the solution can be stored at a concentration range of 0.7 to 2.1 × 106 /µl for up to 5 days at 20-24 °c with continuous agitation in the terumo bct elp bag [citrated polyvinyl chloride (pvc)] [see clinical studies (14).] do not infuse isoplate solution directly to the patients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

wockhardt limited - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - fexofenadine hydrochloride 30 mg - antihistamine temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: - runny nose - sneezing - itchy, watery eyes - itching of the nose or throat

Irska - angleščina - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - sodium chloride; glucose - solution for infusion - 0.9/5 percent weight/volume - salt solutions; sodium chloride

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - normal saline can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - sodium chloride - solvent for parenteral use - 0.9 %v/w - electrolyte solutions; sodium chloride

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 40 g/l; potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 1.8 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride (0.224%), sodium chloride (0.18%), and glucose (4%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.